First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer

BACKGROUND: Prostate cancer remains dependent of androgen receptor (AR) signalling, even after emergence of castration resistance. EZN-4176 is a third-generation antisense oligonucleotide that binds to the hinge region (exon 4) of AR mRNA resulting in full-length AR mRNA degradation and decreased AR...

Descripción completa

Detalles Bibliográficos
Autores principales: Bianchini, D, Omlin, A, Pezaro, C, Lorente, D, Ferraldeschi, R, Mukherji, D, Crespo, M, Figueiredo, I, Miranda, S, Riisnaes, R, Zivi, A, Buchbinder, A, Rathkopf, D E, Attard, G, Scher, H I, de Bono, J, Danila, D C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833213/
https://www.ncbi.nlm.nih.gov/pubmed/24169353
http://dx.doi.org/10.1038/bjc.2013.619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833213/
https://www.ncbi.nlm.nih.gov/pubmed/24169353
http://dx.doi.org/10.1038/bjc.2013.619

Ejemplares similares